Compare Brookfield Infrastructure Partners LP (BIP) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Brookfield Infrastructure Partners LP vs Sanofi SA — how do they compare? Brookfield Infrastructure Partners LP trades at $39.54 (market cap $18.10B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 5.8× Brookfield Infrastructure Partners LP's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| BIP | SNY | |
|---|---|---|
Market Cap | $18.10B | $104.30B |
Sector | Industrials | Health |
52-Week High | $42.62 | $52.34 |
52-Week Low | $29.81 | $41.33 |
Enterprise Value | $77.05B | $124.19B |
Dividend Yield | 4.62% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Brookfield Infrastructure Partners (BIP) trades at $39.55, up 4.13% in the last session, with a bullish technical signal and strong analyst support. Recent earnings misses contrast with positive cash flow trends and a 6.97 EV/EBITDA valuation. News highlights dividend appeal and corporate simplification efforts, while institutional interest remains robust.
Outlook is cautiously optimistic given high analyst buy ratings and a $44.67 price target, but risks include earnings volatility and margin pressure. The stock offers income potential with dividends, though net income declined to $652M in 2026. Investors should weigh solid infrastructure assets against execution challenges.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Brookfield Infrastructure Partners LP
Brookfield Infrastructure owns and operates high-quality global assets across utilities, transport, midstream, and data sectors. It focuses on generating stable, long-term cash flows from essential infrastructure.
Read more on BIP →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
